as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹616.05
Change
-4.3 (-0.69%)
Open
₹620.6
Prev. Close
₹620.35
Day High
₹620.6
Day Low
₹612.45
Volume Analysis
Traded
2,745
Delivered
1,720
Delivery %
62.66%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (2)
- •Promoter holding is rising
- •Strong operating margin (28.0%)
Weaknesses (0)
No signal for this stock
Opportunities (2)
- •Strong 3-year EPS growth (19.7%)
- •Strong 3-year revenue growth (30.5%)
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹628.44 | ₹624.52 | ₹620.29 | ₹616.37 | ₹612.14 | ₹608.22 | ₹603.99 |
| Fibonacci | ₹624.52 | ₹621.41 | ₹619.48 | ₹616.37 | ₹613.26 | ₹611.33 | ₹608.22 |
| Camarilla | ₹618.29 | ₹617.54 | ₹616.8 | ₹616.37 | ₹615.3 | ₹614.56 | ₹613.81 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
—
1 Week
-4.24%
1 Month
-5.16%
3 Months
+21.37%
6 Months
—
1 Year
—
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹106.53
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
12.13%
Net margin 13.04% × asset turnover 0.75x × equity multiplier 1.24x
Company Overview
Sector
Healthcare
Market Cap
₹798 Cr
P/E (TTM)
65.9
ROE
10.8%
Book Value
₹129.0
Face Value
₹10.0
Source: Screener.in (Consolidated figures) — data as of 16 Nov 2026. Not investment advice.
TopFund Analysis
Shree Ganesh Remedies Ltd holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 66/100. The strongest factor is Financial Strength (100/100), while Valuation (20/100) is the weakest area to weigh before deciding. Notably: Promoter holding is rising; strong operating margin (28.0%). Strong 3-year EPS growth (19.7%).
TopFund Score — Fundamentals Quality
66/100 — GoodData confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company has reduced debt.
- −Though the company is reporting repeated profits, it is not paying out dividend
- −Debtor days have increased from 80.8 to 109 days.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Audio recording of Shree Ganesh Remedies' earnings call held on November 14, 2026.
Shree Ganesh Remedies invites investors to Q2 and H1FY27 earnings call on 14 November 2026.
Shree Ganesh Remedies reported Q2/H1FY27 results; commenced commercial production of two intermediates and completed Block 7A.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2021 | Dec 2021 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 17 | 21 | 37 | 25 | 32 | 27 | 24 | 25 | 30 | 21 | 33 | 14 | 23 |
| Expenses + | 13 | 15 | 20 | 17 | 21 | 17 | 15 | 17 | 21 | 14 | 22 | 11 | 19 |
| Operating Profit | 4 | 6 | 17 | 8 | 11 | 10 | 10 | 7 | 10 | 7 | 11 | 3 | 4 |
| OPM % | 26.22% | 27.31% | 45.38% | 32.81% | 34.98% | 36.64% | 40.44% | 29.59% | 31.73% | 31.88% | 34.28% | 23.33% | 16.92% |
| Other Income + | 0 | 1 | 1 | 1 | 0 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 |
| Depreciation | 1 | 1 | 2 | 2 | 2 | 3 | 2 | 2 | 3 | 3 | 3 | 2 | 3 |
| Profit before tax | 4 | 6 | 16 | 6 | 9 | 8 | 9 | 5 | 7 | 4 | 9 | 2 | 2 |
| Tax % | 22.76% | 25.4% | 22.46% | 26.7% | 25.81% | 27.89% | 24.83% | 25.0% | 26.23% | 22.36% | 28.21% | 27.45% | 28.19% |
| Net Profit + | 3 | 4 | 13 | 5 | 6 | 5 | 7 | 3 | 5 | 3 | 6 | 1 | 2 |
| EPS in Rs | 3 | 3 | 10 | 4 | 5 | 4 | 5 | 3 | 4 | 2 | 5 | 1 | 1 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | 47 | 59 | — | — | — | — | -35 | 0 | -6 | -22 | 36 | -42 | -23 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 16 | 16 | 20 | 27 | 35 | 64 | 49 | 126 | 109 | 109 | 92 |
| Expenses + | 14 | 14 | 16 | 22 | 26 | 52 | 35 | 84 | 69 | 74 | 67 |
| Operating Profit | 2 | 2 | 4 | 5 | 9 | 13 | 14 | 42 | 39 | 35 | 25 |
| OPM % | 13.0% | 12.0% | 21.0% | 19.0% | 25.0% | 20.0% | 28.0% | 33.0% | 36.0% | 32.0% | 28.0% |
| Other Income + | 0 | 0 | 0 | 2 | 1 | 4 | 2 | 3 | 4 | 3 | 4 |
| Interest | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 2 | 4 | 3 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 6 | 10 | 10 | 10 |
| Profit before tax | 2 | 2 | 4 | 6 | 9 | 14 | 13 | 38 | 31 | 24 | 16 |
| Tax % | 33.0% | 34.0% | 33.0% | 28.0% | 28.0% | 23.0% | 25.0% | 26.0% | 26.0% | 26.0% | — |
| Net Profit + | 1 | 1 | 3 | 5 | 6 | 10 | 10 | 28 | 23 | 18 | 12 |
| EPS in Rs | 1 | 1 | 3 | 4 | 5 | 9 | 8 | 23 | 18 | 14 | 9 |
| Dividend Payout % | 0.0% | 0.0% | 0.0% | 19.0% | 18.0% | 13.0% | 18.0% | 2.0% | 0.0% | 0.0% | — |
| Sales growth | -10 | -6 | 27 | 36 | — | 82 | -23 | — | -14 | 1 | -14 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 | Mar 2020 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 12 | 13 | 15 | 20 | 25 | 33 | 109 | 132 | 150 | 153 |
| Borrowings + | 0 | 0 | 0 | 2 | 1 | 4 | 36 | 38 | 31 | 26 |
| Other Liabilities + | 2 | 2 | 5 | 5 | 7 | 9 | 12 | 8 | 14 | 18 |
| Total Liabilities | 15 | 16 | 21 | 36 | 41 | 55 | 171 | 192 | 208 | 210 |
| Fixed Assets + | 4 | 4 | 4 | 6 | 14 | 20 | 81 | 95 | 105 | 102 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 17 | 9 | 13 | 16 |
| Investments | 0 | 0 | 0 | 4 | 4 | 3 | 5 | 18 | 13 | 11 |
| Other Assets + | 11 | 11 | 17 | 25 | 23 | 32 | 69 | 70 | 78 | 81 |
| Total Assets | 15 | 16 | 21 | 36 | 41 | 55 | 171 | 192 | 208 | 210 |
| Equity Capital | 1 | 1 | 1 | 9 | 9 | 9 | 13 | 13 | 13 | 13 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | -1 | -2 | 2 | -1 | -5 | 5 | 3 | 30 | 31 | 24 |
| Cash from Investing Activity + | 1 | 1 | 0 | -3 | 0 | -3 | -1 | -33 | -35 | -9 |
| Cash from Financing Activity + | 0 | 0 | 0 | 8 | 0 | 0 | -1 | 10 | -1 | -12 |
| Net Cash Flow | -1 | 0 | 2 | 4 | -5 | 1 | 2 | 7 | -6 | 3 |
| Free Cash Flow | -1 | -2 | 2 | 0 | -5 | 5 | 3 | -1 | 7 | 7 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | -58 | -79 | 44 | -18 | -60 | 37 | 24 | 92 | 104 | 82 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 30.66% | 30.67% | 30.66% | 29.5% | 27.19% | 27.2% | 27.2% | 27.19% | 27.2% | 27.16% | 26.65% | 26.17% |
| Promoters | 69.33% | 69.33% | 69.33% | 70.49% | 72.8% | 72.8% | 72.8% | 72.8% | 72.8% | 72.83% | 72.83% | 72.83% |
| FII | 0.0% | 0.0% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.0% | 0.0% | 0.0% | 0.0% |
| DII | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.52% | 0.99% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Shree Ganesh Remedies Ltd (this stock) | 798 | 65.9 | 4.79 | 10.8% |
| Kilitch Drugs India Ltd | 805 | 33.4 | 2.79 | 10.6% |
| Zim Laboratories Limited | 756 | 365.0 | 2.59 | 1.59% |
| Gaudium Ivf N Women H L | 740 | 32.0 | 4.55 | 24.6% |
| Health X Platform Limited | 862 | 510.0 | 1.36 | 0.44% |
| Wanbury Limited | 676 | 20.3 | 4.3 | 76.5% |
| Themis Medicare Ltd. | 929 | 624.0 | 2.33 | 0.41% |
Which Mutual Funds Hold Shree Ganesh Remedies Ltd?
Frequently Asked Questions about Shree Ganesh Remedies Ltd
Shree Ganesh Remedies Ltd (SGRL) closed at ₹616.05 on NSE on 19 November 2026, down 4.3 (0.69%) from the previous close.
Shree Ganesh Remedies Ltd trades on the NSE (National Stock Exchange of India) under the symbol SGRL.
Shree Ganesh Remedies Ltd has a trailing twelve-month P/E (price-to-earnings) ratio of 65.9.
Shree Ganesh Remedies Ltd has a dividend yield of 0.0%.
Shree Ganesh Remedies Ltd's 52-week high is ₹759.0 and its 52-week low is ₹381.0.
Shree Ganesh Remedies Ltd has a market capitalisation of ₹798 crore.
Shree Ganesh Remedies Ltd has a TopFund Quality Score of 66/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Shree Ganesh Remedies Ltd?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.